Tesamorelin improves fat quality by increasing fat density, meaning the fat tissue becomes healthier with smaller fat cells, better blood supply, and less inflammation, even after accounting for fat loss.

Visceral fat is metabolically active tissue that disrupts insulin sensitivity and metabolic function, and tesamorelin reduces it through mechanisms that improve fat quality, muscle composition, and mitochondrial efficiency, leading to long-term metabolic resilience.

Tesamorelin has robust human evidence demonstrating specific reductions in metabolically harmful fat depots including visceral, liver, and intramuscular fat.

Administration of tesamorelin results in a statistically significant reduction in visceral adipose tissue volume compared to placebo, with a mean reduction of approximately 11% after 6 months of treatment.

A hormone treatment called tesamorelin decreases belly fat by 42 square centimeters more than a placebo in people with HIV who have excess abdominal fat after six months of treatment.

The same drug that reduces belly fat in HIV patients also makes the fat under the skin denser and healthier-looking on scans, even when the amount of fat doesn’t change much.